Commercialization of Accelerate Arc system, which includes
the Accelerate Arc Module and BC kit, unlocks the path to
automated, rapid microbial ID for positive blood cultures across
the large installed base of MALDI system users. The Accelerate Arc
system can cut hours of wait time, eliminate laborious hands-on
sample prep, and offer significant cost savings for healthcare
facilities compared to current methods.
TUCSON,
Ariz., May 16, 2022 /PRNewswire/ -- Accelerate
Diagnostics, Inc. (NASDAQ: AXDX) an in-vitro diagnostics company
dedicated to providing solutions for the global challenges of
antibiotic resistance and sepsis, today announced commercialization
of its new Accelerate Arc Module and BC kit.
"On the heels of publishing robust data at the 32nd European
Congress for Clinical Microbiology and Infectious Diseases
demonstrating the value of using the automated Accelerate Arc
Module and BC kit, we're excited to announce this product is now
registered as an IVD with the FDA and will soon be available to
healthcare facilities in the U.S. market," said John Meduri, Chief Strategy Officer for
Accelerate Diagnostics. "Arc in its early days of commercialization
has already generated numerous evaluations and in-bound interest
from potential commercial partners. Using our system, the total
cost to rapidly identify organisms from positive blood cultures is
significantly less than what laboratories are paying today for a
rapid molecular ID solution."
Designed for labs with MALDI platforms, the Accelerate Arc
Module and BC kit is a novel application of inline centrifugation
and automated sample prep techniques, which together with the blood
culture (BC) kit, provides a suspension of cleaned microbial cells
for direct transfer to a MALDI spotting plate.
The simple load-and-go workflow eliminates the need for batching
multiple specimen tests, cutting hours off the wait for microbial
ID results for positive blood cultures. The Accelerate Arc Module
requires just 2-3 minutes of hands-on time to run and is simple
enough to be used on all shifts, by any laboratory technician,
freeing up valuable technician time by automating the MALDI
workflow. Further, this automated, rapid workflow that the
Accelerate Arc system avails is the perfect companion to the
Accelerate PhenoTest® BC kit AST configuration enabling
laboratories to report identification and antimicrobial
susceptibility test results directly from positive blood cultures
days earlier than current standard-of-care methods.
For further information on the Accelerate Arc Module, please
visit the Accelerate Diagnostics products page linked here.
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. is an in vitro diagnostics company
dedicated to providing solutions for the global challenges of
antibiotic resistance and sepsis. The Accelerate Pheno®
system and Accelerate PhenoTest® BC kit combine several
technologies aimed at reducing the time clinicians must wait to
determine the most optimal antibiotic therapy for deadly
infections. The FDA cleared system and kit fully automate the
sample preparation steps to report phenotypic antibiotic
susceptibility results in approximately 7 hours direct from
positive blood cultures. Recent external studies indicate the
solution offers results 1–2 days faster than existing methods,
enabling clinicians to optimize antibiotic selection and dosage
specific to the individual patient days earlier. The Accelerate
Arc™ Module and BC kit is an innovative technology that offers an
automated path to direct MALDI identification for positive blood
cultures and requires a simple workflow with short hands-on-time.
This new sample prep device enables lab technicians to easily
unlock the vast ID capability of MALDI.
"Accelerate Diagnostics" and diamond shaped logos and marks are
registered trademarks of Accelerate Diagnostics, Inc. Any trade,
product or service name referenced in this document using the name
"Accelerate" is a trademark and/or property of Accelerate
Diagnostics, Inc. All other company and product names may be
trademarks, registered trademarks, or service marks of the
companies with which they are associated.
For more information about the company, its products and
technology, or recent publications, visit axdx.com.
Forward-Looking Statements
Certain of the statements made in this press release are forward
looking. Actual results or developments may differ materially from
those projected or implied in these forward-looking statements.
Such forward looking statements include, but are not limited to,
statements regarding expected customer cost savings, and
improvements in workflow times. Information about the risks and
uncertainties faced by Accelerate Diagnostics is contained in the
section captioned "Risk Factors" in the company's most recent
Annual Report on Form 10-K, filed with the Securities and Exchange
Commission on March 14, 2022, and in
any other reports that the company files with the Securities and
Exchange Commission. The company's forward-looking statements could
be affected by general industry and market conditions, and
regulatory approvals. Except as required by federal securities
laws, the company undertakes no obligation to update or revise
these forward-looking statements to reflect new events,
uncertainties, or other contingencies.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/accelerate-diagnostics-announces-commercialization-of-its-accelerate-arc-system-having-completed-ivd-registration-with-fda-301547330.html
SOURCE Accelerate Diagnostics, Inc.